Orphazyme predicts EU rejection after meeting with CHMP
Biotech company Orphazyme is not holding out much hope for an EU approval of its candidate arimoclomol after its meeting with the expert committee CHMP on Wednesday.
by mikkel aabenhus hemmingsen, translated by catherine brett
An indicative vote taken on Wednesday by the CHMP, an expert panel that is part of the European Medicines Agency, did not result in a majority in favor of recommending Orphazyme’s candidate arimoclomol for approval in the region. The CHMP (Committee for Medicinal Products for Human Use) was considering arimoclomol for the indication Niemann Pick type C, a rare metabolic disease also known as NPC.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme elects new board member
For subscribers
Orphazyme gets investor backing for fundraising round
For subscribers
.jpg&w=384&q=75)
